Prognostic and clinicopathological significance of FOXD1 in various cancers: a meta and bioinformation analysis

作者：Xiaohan Liu, Shengyun Min, Qin Zhang, Yan Liu, Zhenhong Zou, Nanye Wang, Bin Zhou · 发表于：Future Science OA · 年份：2023 · DOI：10.2144/fsoa-2023-0085 · 被引用次数：7 · 研究领域：FOXO transcription factor regulation、Cancer-related molecular mechanisms research、RNA modifications and cancer

Aim: To examine both predictive and clinicopathological importance underlying FOXD1 in malignant tumors, our study adopts meta-analysis. Methods: We searched from PubMed, Embase, WOS, Wanfang and CNKI. Stata SE15.1 was used to calculate the risk ratio (HR) as well as relative risk (RR) with 95% of overall confidence intervals (CIs) to assess FOXD1 and overall survival rate (OS), disease-free survival rate (FOXD1) as well as clinicopathological parameters. Results: 3808 individuals throughout 17 trials showed high FOXD1 expression was linked to disadvantaged OS (p < 0.001) and disease-free survival (p < 0.001) and higher TNM stage (p < 0.001). Conclusion: Elevated FOXD1 had worse predictions and clinicopathological parameters in most cancers. The GEPIA database findings also support our results.